Phospho-CYLD (Ser418) Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5105234-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA5105234 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
Phospho-CYLD (Ser418)
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CYLD
Gene Alias
2010013M14Rik; 2900009M21Rik; BRSS; C130039D01Rik; CDMT; Cyld; CYLD lysine 63 deubiquitinase; CYLD1; CYLDI; cylindromatosis (turban tumor syndrome); deubiquitinating enzyme CYLD; EAC; FLJ20180; FLJ31664; FLJ78684; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; Rp1; Rp1h; SBS; TEM; ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; ubiquitin-specific-processing protease CYLD; Unknown (protein for MGC:137952); USPL2
Host Species
Rabbit
Purification Method
sequential chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1540, 312937
Content And Storage
-20°C
Form
Liquid
Applications
Immunohistochemistry (Paraffin), Western Blot
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene Accession No.
Q66H62, Q9NQC7
Gene Symbols
CYLD
Immunogen
A synthesized peptide derived from human CYLD(Accession Q9NQC7), corresponding to amino acid residues around phosphorylated Ser418.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Antibody detects endogenous levels of CYLD only when phosphorylated at Ser418
- CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH
- CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway
- CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway
- It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination
- Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.